HPV Vaccine: Good News, Bad News

Vaccine Stops 2 Cervical Cancer Viruses -- but Only 'Modest' Overall Cancer Protection Seen

From the WebMD Archives

May 9, 2007 -- The Gardasil vaccine is extremely effective in protecting women against precancerous lesions caused by the human papillomavirus types (HPVs) that cause 70% of cervical cancers and most cases of genital warts.

That's the good news from two huge, international clinical trials. The not-so-good news: Among sexually experienced 15- to 26-year-old women -- some of whom already have HPV infection -- the vaccine is far less effective in protecting against dangerous cervical lesions.

The FUTURE 1 trial enrolled nearly 5,500 women aged 16 to 24. The FUTURE II trial enrolled more than 12,000 women aged 15 to 26. Three-year results from both trials appear in the May 10 issue of The New England Journal of Medicine.

Gardasil protects against HPV that is spread mainly during sex. Women often get HPV infections soon after beginning sexual activity, although most HPV infections will not develop into cancer. So the best time to get the vaccine is in the pre-teen years, before age 13.

Or even sooner: The FDA has approved Gardasil for 9- to 26-year-olds, and the CDC has added it to the childhood vaccination schedule. Several states are debating making HPV vaccination mandatory for public school attendance, although all of these measures allow parents to opt out.

In the current studies, the vaccine looked very safe -- and very effective, says FUTURE II investigator Kevin Ault, MD, associate professor of gynecology and obstetrics at Atlanta's Emory University.

"The vaccine's efficacy is the biggest news," Ault tells WebMD. "In FUTURE I, it was 100% effective in preventing precancerous lesions and genital warts, and in FUTURE II it was 98% effective in protecting against high-grade, precancerous cervical lesions."

Different Experts, Different Opinions

Ault's numbers reflect the vaccine's effectiveness against the four HPV strains included in the vaccine -- including cervical-cancer-causing HPV-16 and HPV-18.

But these are only two of the 15 HPV strains known to cause cervical cancer. An editorial accompanying the studies notes that overall, the vaccine was no more than 20% effective in protecting women against high-grade precancerous lesions.

"This gives us a glimpse of what to expect from vaccinating a generation of 15- to 26-year-olds regardless of their sexual exposure," the editorial's co-author, Karen Smith-McCune, MD, tells WebMD. "In that general population, looking at all women who got the vaccine with all types of HPV exposure, efficacy in reducing precancer was modest -- 17% fewer cases of precancer in vaccinated women vs. the placebo group. And if you look at the most significant precancer, grade 3, there is no significant reduction among vaccinated women."


Smith-McCune is associate professor of obstetrics and gynecology at the University of California, San Francisco. She's also the mother of two daughters.

"I am not having my daughters vaccinated because the proven method of reducing their risk with regular Pap screening is very effective," she says. "In the absence of safety and efficacy data in the 11- to 12-year-old age group, and the unknown long-term effect of this vaccine in all age groups, it is too soon to recommend this vaccine."

Gynecologist Brian Slomovitz, MD, of Weill Cornell Medical Center in New York, disagrees with Smith-McCune. He says that even with regular Pap screening, many young women will have to have precancerous cervical lesions removed -- procedures that may result in pregnancy complications.

"Cervical precancers are a big problem, and genital warts are a huge problem," Slomovitz tells WebMD. "The ultimate value of the HPV vaccine is to reduce deaths due to cervical cancer, but it is also valuable for preventing high-grade cervical lesions and genital warts."

Ault agrees with Slomovitz.

"These studies are further proof that what we recommended last year was a good idea: This vaccine should be given to women age 9 to 26," he says.

Smith-McCune insists that too many questions remain about the HPV vaccine to recommend widespread vaccination of girls and young women.

"It is important to counter the sense of urgency of vaccinating the girls with the fact that cervical cancer is not an emergency in the U.S.," she says. "Any improvement that will reduce a woman's risk of cervical cancer is a great thing. We just don't have enough data to support that yet. The studies are ongoing. We have a lot to learn about the impact of this vaccine on precancer and cervical cancer."

WebMD Health News Reviewed by Louise Chang, MD on May 09, 2007


SOURCES: Villa, L.L. The New England Journal of Medicine, May 10, 2007; vol 356: pp 1915-1927. Garland, S.M. The New England Journal of Medicine, May 10, 2007; vol 356: pp 1928-1943. Sawaya, G.F. and Smith-McCune, K. The New England Journal of Medicine, May 10, 2007; vol 356: pp 1991-1993. Agosti, J.M. and Goldie, S.J. The New England Journal of Medicine, May 10, 2007; vol 356: pp 1908-1910. Charo, R.A. The New England Journal of Medicine, May 10, 2007; vol 356: pp 1905-1908. Baden, L.R. The New England Journal of Medicine, May 10, 2007; vol 356: pp 1990-1991. Kevin Ault, MD, associate professor of obstetrics and gynecology, Emory University, Atlanta. Karen Smith-McCune, MD, associate professor of obstetrics and gynecology. University of California, San Francisco. Brian Slomovitz, MD, assistant professor of gynecologic oncology, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York.

© 2007 WebMD, Inc. All rights reserved.